China Sets Aside RMB 2.7 Billion To Advance Biopharma Tech
This article was originally published in PharmAsia News
This year, China’s National Development Reform Commission has earmarked RMB 1.2 billion in funding for projects relating to development of generics and protein biopharma and vaccines.
You may also be interested in...
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.